IP Landscape - builds robustly through to Year 3
⎖ Shear sensitive nanoparticle aggregates for stenotic lesions
⎖ Owner: Harvard University (HU)
⎖ Status: PCT/US2011/049691 Granted (AU, CN, EU)
⎖ Shear-activated nanoparticle aggregates for cerebral collateral circulation
⎖ Owners: UON & HU
⎖ Status: PCT/US2021/052402 Granted (AU), Pending (Canada,
⎖ Lyophilized powder, optimised for stable shelf-life and acute IV delivery, Manufacturing processes
⎖ XR Expansion of indication to treat in-patient management once pt stabilized (pts not eligible for tPA or thrombectomy)
⎖ Combination use with tPA
⎖ Combination with novel neuroprotective agents
⎖ Data generation via tack-on to in-progress clinical trials
⎖ Designed for clinicians in-hospital or paramedics in-field
⎖ Self-contained dry-powder particle storage & re-suspension
⎖ Flow-limited mixing & IV delivery
⎖ Integrates with existing gold standard stroke care
⎖ JV Harvard & Newcastle University
⎖ UON lead, Australian Pty Ltd
⎖ 20% joint university ownership
⎖ 80% founder ownership
⎖ International drug development and clinical collaboration
⎖ Strong foundational patents with broad coverage, FTO complete.
⎖ Identified areas for further filings
⎖ Dedicated device to restrict shear flow activation prior to administration
⎖ XR long-acting delivery in post-stroke recovery
⎖ New indications; kidney, diabetes, other “occlusive disorders”, including pulmonary embolism, atherosclerosis.
⎖ Future combination use with stroke therapeutics, neuroprotective agents
⎖ Investment & Industry engagement to drive further clinical indications,licensing opportunities and exit
